Comparative Pharmacology
Head-to-head clinical analysis: IV PERSANTINE versus MINOXIDIL FOR WOMEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IV PERSANTINE versus MINOXIDIL FOR WOMEN.
IV PERSANTINE vs MINOXIDIL (FOR WOMEN)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits adenosine deaminase and phosphodiesterase, increasing intracellular cAMP and adenosine; causes coronary vasodilation and inhibits platelet aggregation.
Minoxidil is a potassium channel opener. It activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arterioles, causing peripheral vasodilation and reduced blood pressure. For hair growth, the exact mechanism is unclear but involves increased cutaneous blood flow, stimulation of hair follicle proliferation via direct effects on dermal papilla cells, and prolongation of the anagen phase.
0.14 mg/kg/min intravenous infusion over 4 minutes for myocardial perfusion imaging.
Topical: 2% or 5% solution, 1 mL applied to the scalp twice daily (morning and evening).
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in adults; may be prolonged in patients with hepatic impairment.
Terminal elimination half-life: approximately 4.2 hours in patients with normal renal function; may extend to 24+ hours in renal impairment.
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; renal excretion of unchanged drug is minimal (<1%); biliary/fecal elimination accounts for approximately 90% of the dose.
Primarily renal (90% as unchanged drug and metabolites; 10% via feces via biliary elimination).
Category C
Category A/B
Vasodilator
Vasodilator / Hair Growth Stimulant